The Middle East is one of the world's largest outbound medical-tourism markets — patients from the UAE, Saudi Arabia, Qatar and Kuwait seek quality care abroad every year. Increasingly, they're looking at China. Here's what the cost data shows and why.
Updated August 2026. For decades, the Gulf Cooperation Council (GCC) region has been a significant source of outbound medical tourists. Despite massive health-spending investments in UAE, Saudi Arabia, and Qatar, complex treatments remain expensive — and certain advanced therapies simply aren't available locally. Patients historically went to the UK, US, Germany, Turkey, Thailand or India. China is emerging as a competitive alternative, offering comparable technology at lower prices, plus unique access to FDA-approved drugs in the Hainan Boao Lecheng zone that aren't registered anywhere else in the region.
The GCC region spends billions annually on healthcare infrastructure. The UAE alone operates dozens of JCI-accredited hospitals in Dubai, Abu Dhabi and Sharjah, alongside ambitious new facilities across the Emirates. Saudi Vision 2030 and Qatar National Vision 2030 both prioritise healthcare modernisation. Yet outbound medical tourism persists because:
Note: Price figures below are approximate ranges based on publicly reported GCC private-hospital costs and international medical-tourism industry publications. They represent typical self-pay or uninsured scenarios for complex procedures.
The following table places typical Middle East private-sector prices against published Chinese hospital cost ranges from our partner network. China figures come from verifiable hospital pricing sheets collected 2025–2026.
| Treatment | GCC private (approx.) | China all-in | Savings |
|---|---|---|---|
| Cancer — CAR-T cell therapy | $500,000+ | $89,000–170,000 | ~70% |
| Cancer — Immunotherapy (per year) | $150,000–300,000 | $25,000–45,000 | ~75–85% |
| Knee replacement | $8,000–18,000 | $6,000–8,000 | ~30–50% |
| Hip replacement | $10,000–20,000 | $8,000–12,000 | ~30–50% |
| Cardiac bypass | $25,000–55,000 | $10,000–18,000 | ~50–65% |
| Executive health checkup | $3,000–8,000 | $1,000–5,000 | ~30–50% |
| IVF (per cycle) | $6,000–15,000 | $4,000–6,000 | ~30–60% |
| Diagnostics (PET-CT, biopsy panels) | $5,000–12,000 | $1,500–4,000 | ~60–70% |
These China figures match those on our cancer treatment cost guide and are sourced from the same published hospital price lists used for our US and Australia comparisons.
GCC patients currently split between several destinations — Turkey (the dominant option for Europeans and Arabs), India (volume-driven, low-cost), and Thailand (luxury-oriented). China competes by offering:
The medical-tourism broker space globally includes numerous intermediaries charging upfront deposits with no recourse. For GCC patients navigating the online space, this risk is amplified by currency-exchange complexity and cross-border payment frictions. Our escrow structure eliminates the issue entirely:
Outbound medical tourism from the Gulf is well-established. The primary drivers include cost — even wealthy GCC nations face high private-sector charges for complex treatments like cardiac bypass and oncology — and access. Certain advanced therapies approved abroad aren't yet available locally, pushing patients toward Turkey, India, Thailand or increasingly China.
China has growing Arabic-speaking departments at major international hospitals. Direct flights connect Dubai, Riyadh, Doha and other GCC hubs with Beijing, Shanghai and Guangzhou (typically 8–12 hours). Many JCI-accredited hospitals serve substantial numbers of Middle Eastern patients and have experience with Islamic dietary requirements, prayer accommodations, and gender-concordant care preferences.
Turkey and India are the two dominant destinations. China offers comparable or lower pricing on complex procedures (carcinoma, CAR-T therapy, robotic surgery), closer geographic proximity to most GCC cities than India, and — crucially — Boao Lecheng access to FDA-approved drugs not yet registered in the Middle East.
UAE citizens enjoy a 15-day visa-free stay in mainland China. Other GCC nationalities can apply through standard channels (tourist/business visas typically process in 3–5 business days from Gulf-based Chinese consulates). Hainan province offers extended visa-free entry (up to 30 days) to citizens of 86 countries including UAE, Qatar and several GCC-linked states.
Our partner hospitals are accustomed to serving international patients from diverse cultural backgrounds. Halal meal options are routinely accommodated, privacy arrangements respecting modesty preferences are provided, and Arabic interpreters are available at several of the larger international departments. We confirm specific accommodations during your case review.
Attach your diagnosis. We'll respond within one business day.